Related Experiment Video
Updated: Sep 30, 2025
Immunoglobulin Gene Sequence Analysis In Chronic Lymphocytic Leukemia: From Patient Material To Sequence Interpretation
Published on: November 26, 2018
Large granular lymphocytic leukemia: a brief review
Ekta Rahul1, Aparna Ningombam2, Shreyam Acharya2
1Laboratory Oncology Unit, Dr. B.R.A.I.R.C.H, All India Institute of Medical Sciences New Delhi, India.
Insights
Large granular lymphocyte (LGL) leukemia is a rare disorder affecting T cells or NK cells. Understanding its molecular pathways and clinical features is crucial for developing targeted therapies and improving patient outcomes.
Area of Science:
- Hematology
- Immunology
- Oncology
Background:
- Large granular lymphocyte (LGL) leukemia is a rare chronic lymphoproliferative disorder.
- It originates from cytotoxic lymphocytes, classified as T-cell or NK-cell derived.
- Subtypes include chronic T-cell leukemia, chronic NK-cell lymphocytosis, and aggressive NK-cell LGL leukemia.
Purpose of the Study:
- To provide a comprehensive overview of LGL leukemia.
- To discuss its epidemiology, pathophysiology, and clinical manifestations.
- To review current and emerging treatment strategies.
Main Methods:
- Review of existing literature on LGL leukemia.
- Analysis of molecular pathways involved in LGL proliferation.
- Discussion of clinical features, diagnostic approaches, and treatment outcomes.
Main Results:
- LGL leukemia is characterized by neutropenia, anemia, and thrombocytopenia, often associated with autoimmune conditions.
- Molecular pathways like JAK-STAT3 and PI3K/AKT are implicated in clonal proliferation.
- Indolent cases typically have a good prognosis, with aggressive NK-cell LGL leukemia being an exception.
Conclusions:
- Advances in understanding molecular pathways are guiding the development of targeted therapies.
- Effective management relies on addressing clinical features and considering immunomodulators and targeted treatments.
- Further research and clinical trials are needed due to the disease's rarity.
Abstract:
LGL leukemia is a rare chronic lymphoproliferative disorder of cytotoxic lymphocytes which can be immunophenotypically either T cell or NK cell-derived. According to the World Health Organization classification, it can be divided into three subtypes: chronic T-cell leukemia and chronic natural killer cell lymphocytosis, and aggressive natural killer cell LGL leukemia. Clonal proliferation of large granular lymphocytes can be because of stimulation of various molecular pathways namely JAK-STAT3 pathway, FAS/FAS-L pathway, RAS-RAF-1-MEK1-ERK pathway, PI3K/AKT pathway, NF-KB pathway, and Sphingolipid Rheostat pathways. The most common clinical features presenting with this leukemia are neutropenia, anemia, thrombocytopenia. This leukemia is also associated with various autoimmune conditions. It usually has an indolent course except for the aggressive NK cell LGL leukemia. The cause of death in the indolent cases was mostly due to infectious complications related to the neutropenia associated with the disease. The rarity of the disease coupled with the availability of only a handful of clinical trials has been a hindrance to the development of a specific treatment. Most of the cases are managed with immunomodulators. The advances in the knowledge of molecular pathways associated with the disease have brought few targeted therapies into the limelight. We discuss here the evolution, epidemiology, demographic profile, pathophysiology, differential diagnosis, the available treatment options along with the survival and prognostic variables which may help us in better understanding and better management of the disease and hopefully, paving the way for a targeted clinical approach.
